FOLH1 and metastatic prostate carcinoma: In metastatic prostate cancer patients, the diagnostic performances of both [18F]PSMA-1007 PET/CT and [18F]DCFPyL PET/CT are also highly promising for accurate local staging in recurrent disease and has been shown to be at least equivalent to [68Ga]Ga-PSMA-11 [57,58,59,60].